- Previous Close
110.18 - Open
109.49 - Bid 109.42 x 900
- Ask 109.70 x 800
- Day's Range
109.39 - 110.30 - 52 Week Range
99.14 - 134.63 - Volume
9,702,116 - Avg. Volume
9,367,529 - Market Cap (intraday)
278.246B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
20.33 - EPS (TTM)
5.40 - Earnings Date Oct 31, 2024
- Forward Dividend & Yield 3.08 (2.81%)
- Ex-Dividend Date Sep 16, 2024
- 1y Target Est
139.94
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
www.merck.com70,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MRK
View MorePerformance Overview: MRK
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRK
View MoreValuation Measures
Market Cap
278.25B
Enterprise Value
304.68B
Trailing P/E
20.33
Forward P/E
10.96
PEG Ratio (5yr expected)
0.07
Price/Sales (ttm)
4.48
Price/Book (mrq)
6.38
Enterprise Value/Revenue
4.88
Enterprise Value/EBITDA
14.80
Financial Highlights
Profitability and Income Statement
Profit Margin
21.99%
Return on Assets (ttm)
11.38%
Return on Equity (ttm)
33.38%
Revenue (ttm)
62.48B
Net Income Avi to Common (ttm)
13.74B
Diluted EPS (ttm)
5.40
Balance Sheet and Cash Flow
Total Cash (mrq)
11.35B
Total Debt/Equity (mrq)
86.57%
Levered Free Cash Flow (ttm)
11.79B
Research Analysis: MRK
View MoreCompany Insights: MRK
MRK does not have Company Insights
Research Reports: MRK
View MoreMerck's Wide Moat Is Supported by Leading Oncology Drug Keytruda and a Growing Pipeline
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingPrice TargetMerck Holds a Strong Portfolio of Vaccines and Drugs, Led by Cancer Drug Keytruda
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingPrice TargetLarge Cap US Pick List - September 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Large Cap US Pick List - August 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.